行情

VKTX

VKTX

Viking Therapeut
NASDAQ

实时行情|Nasdaq Last Sale

6.54
-0.17
-2.46%
盘前: 6.60 +0.07 +0.99% 09:00 10/21 EDT
开盘
6.66
昨收
6.70
最高
6.80
最低
6.45
成交量
74.56万
成交额
--
52周最高
15.69
52周最低
6.15
市值
4.72亿
市盈率(TTM)
-18.3361
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VKTX 新闻

  • The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
  • Benzinga.10/10 11:31
  • Ligand's Shots On Goal Target (Podcast Transcript)
  • Seeking Alpha - Article.10/09 11:15
  • NGM Bio down 17% premarket on underwhelming data on NASH candidate
  • Seeking Alpha - Article.10/07 13:16
  • Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
  • PR Newswire.09/25 12:30

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

VKTX 简况

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
展开

Webull提供Viking Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。